Elite Pharmaceuticals (ELTP) Stock Price, News & Analysis

Company Overview

Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP) is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and niche pharmaceutical products. The company’s portfolio primarily consists of orally administered dosage forms, including tablets and capsules, and it also provides contract manufacturing and development services for pharmaceutical partners.

Elite has developed products in several therapeutic categories, including controlled substances and other prescription medicines. Its activities have included the development and commercialization of generic products, as well as the use of proprietary drug-delivery and abuse-deterrence technologies for certain opioid formulations. Products may be marketed directly by Elite or through licensing, distribution and commercialization arrangements with other pharmaceutical companies.

Founded in 1984 and based in Northvale, New Jersey, Elite primarily serves the U.S. pharmaceutical market. The company is led by Nasrat Hakim, who serves as president and chief executive officer. Its operations include formulation development, regulatory support, manufacturing and the commercial supply of pharmaceutical products.

Key Stats

• Today's Range: $0.21 to $0.25
• 50-Day Range: $0.22 to $0.28
• 52-Week Range: $0.21 to $0.69
• Volume: 866,126 shs
• Average Volume: 550,102 shs
• Market Capitalization: $258.59 million
• P/E Ratio: 6.00
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Elite Pharmaceuticals Stock Analysis - MarketRank™

Elite Pharmaceuticals scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Elite Pharmaceuticals.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Elite Pharmaceuticals is 6.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.09.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elite Pharmaceuticals is 6.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.39.

Price to Book Value per Share Ratio

Elite Pharmaceuticals has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.32% of the float of Elite Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Elite Pharmaceuticals has a short interest ratio ("days to cover") of 2.76, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elite Pharmaceuticals has recently decreased by 1.41%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elite Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Elite Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for ELTP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elite Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.42% of the stock of Elite Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

0.01% of the stock of Elite Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/12/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ELTP
• CIK: 1053369
• Web: www.elitepharma.com
• Phone: (201) 750-2646
• Fax: 201-750-2755
• Employees: 65
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.04
• Trailing P/E Ratio: 6.00
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $44.87 million
• Net Margins: 40.19%
• Pretax Margin: 46.16%
• Return on Equity: 44.58%
• Return on Assets: 29.54%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 3.76
• Quick Ratio: 2.97

Sales & Book Value

• Annual Sales: $148.87 million
• Price / Sales: 1.74
• Cash Flow: $0.03 per share
• Price / Cash Flow: 8.99
• Book Value: $0.09 per share
• Price / Book: 2.67

Miscellaneous

• Outstanding Shares: 1,077,470,000
• Free Float: 922,099,000
• Market Cap: $258.59 million
• Optionable: Not Optionable
• Beta: 0.44